In vivo hepatogenic capacity and therapeutic potential of stem cells from human exfoliated deciduous teeth in liver fibrosis in mice
- 3.1k Downloads
Liver transplantation is a gold standard treatment for intractable liver diseases. Because of the shortage of donor organs, alternative therapies have been required. Due to their potential to differentiate into a variety of mature cells, stem cells are considered feasible cell sources for liver regeneration. Stem cells from human exfoliated deciduous teeth (SHED) exhibit hepatogenic capability in vitro. In this study, we investigated their in vivo capabilities of homing and hepatocyte differentiation and therapeutic efficacy for liver disorders in carbon tetrachloride (CCl4)-induced liver fibrosis model mice.
We transplanted SHED into CCl4-induced liver fibrosis model mice through the spleen, and analyzed the in vivo homing and therapeutic effects by optical, biochemical, histological, immunological and molecular biological assays. We then sorted human leukocyte antigen-ABC (HLA-ABC)-positive cells from primary CCl4-damaged recipient livers, and analyzed their fusogenicity and hepatic characteristics by flow cytometric, genomic DNA, hepatocyte-specific gene assays. Furthermore, we examined the treatment effects of HLA-positive cells to a hepatic dysfunction by a secondary transplantation into CCl4-treated mice.
Transplanted SHED homed to recipient livers, and expressed HLA-ABC, human hepatocyte specific antigen hepatocyte paraffin 1 and human albumin. SHED transplantation markedly recovered liver dysfunction and led to anti-fibrotic and anti-inflammatory effects in the recipient livers. SHED-derived HLA-ABC-positive cells that were sorted from the primary recipient liver tissues with CCl4 damage did not fuse with the host mouse liver cells. Sorted HLA-positive cells not only expressed human hepatocyte-specific genes including albumin, cytochrome P450 1A1, fumarylacetoacetase, tyrosine aminotransferase, uridine 5′-diphospho-glucuronosyltransferase, transferrin and transthyretin, but also secreted human albumin, urea and blood urea nitrogen. Furthermore, SHED-derived HLA-ABC-positive cells were secondary transplanted into CCl4-treated mice. The donor cells homed into secondary recipient livers, and expressed hepatocyte paraffin 1 and human albumin, as well as HLA-ABC. The secondary transplantation recovered a liver dysfunction in secondary recipients.
This study indicates that transplanted SHED improve hepatic dysfunction and directly transform into hepatocytes without cell fusion in CCl4-treated mice, suggesting that SHED may provide a feasible cell source for liver regeneration.
KeywordsHepatic Stellate Cell Human Hepatocyte Recipient Liver Stem Cell From Human Exfoliate Deciduous Dental Pulp Tissue
Carboxyfluorescein diacetate succinimidyl ester
Epidermal growth factor
Enzyme-linked immunosorbent assay
Fibroblast growth factor 2
Glyceraldehyde 3-phosphate dehydrogenase
Hepatocyte growth factor
Human leukocyte antigen
Major histocompatibility complex
Mesenchymal stem cell
Stem cells from human exfoliated deciduous teeth
Transforming growth factor β1
Interleukin-17-producing helper T
Tissue inhibitor of metalloproteinase
Tumor necrosis factor alpha
Regulatory T cells
Alpha smooth muscle actin
Hepatic fibrosis is a severe chronic condition that occurs as a result of various congenital and acquired hepatic disorders, including viral, drug-induced, cholestatic, metabolic, and autoimmune diseases. Cirrhosis, the most advanced stage of hepatic fibrosis, usually progresses to hepatocellular carcinoma, resulting in liver failure without the liver’s usual self-regenerative capability. Unfortunately, current pharmaceutical and immunological treatments are unable to cure patients with hepatic fibrosis and/or cirrhosis. Liver transplantation is therefore the only treatment with clinical success. However, few patients benefit from organ grafting because of high medical expenses, the long-term wait for a donor liver, organ rejection, and complications . Hepatocyte transplantation as an alternative is also associated with a limited cell supply and minimal engraft efficacy . Another alternative therapy is therefore required urgently for hepatic fibrosis and/or cirrhosis. A concept of stem cell-based tissue engineering and regenerative medicine is expected to provide novel and promising therapeutics for refractory liver diseases .
Human mesenchymal stem cells (MSCs) exhibit self-renewal and multipotency into a variety of mature cells, including hepatocytes . Human MSCs have been identified in a variety of human tissues, including bone marrow , adipose tissue , umbilical cord blood , amniotic fluid stem cells , and dental pulp tissue . Recent studies also evaluate immunomodulatory effects of MSCs . MSCs are therefore considered a feasible cell source for tissue engineering and regenerative medicine . Some clinical phase I, I/II, and II trials have demonstrated that human MSC transplantation recovers hepatic function in liver cirrhosis patients [12, 13, 14], indicating that human MSCs might be a promising candidate for treatments of liver dysfunction.
Stem cells from human exfoliated deciduous teeth (SHED) are a major focus area in tissue engineering and regenerative medicine. SHED are discovered in remnant dental pulp tissues of human exfoliated deciduous teeth, and share MSC characteristics, including fibroblastic features, clonogenicity, cell surface antigen expression, cell proliferative capacity, and multidifferentiation potency . SHED also modulate immune responses of interleukin-17-producing helper T (Th17) cells, regulatory T cells (Tregs), and dendritic cells [16, 17]. Recent studies have evaluated the latent potential of SHED in tissue engineering for bone regeneration [18, 19] and cell-based therapy for a variety of refractory systemic diseases, including systemic lupus erythematous, spinal cord injury, Parkinson’s disease, and diabetes [16, 20, 21, 22]. Furthermore, cryopreservation of dental pulp tissues from human deciduous teeth has succeeded .
Accumulating evidence has demonstrated that a variety of human MSCs, including bone marrow-derived, adipose tissue-derived, umbilical cord blood-derived, and Wharton’s jelly-derived MSCs, are capable of differentiating into hepatocyte-like cells in vivo in animal models of hepatic failure [24, 25, 26]. Advanced tissue engineering techniques accelerate a transdifferentiation ability of human MSCs into hepatocytes [27, 28]. In comparison with other human tissues, exfoliated deciduous teeth offer significant advantages of less ethical controversies and readily accessible source, easy and minimally invasive collection, and retain high stem cell potential such as cell proliferation, multipotency, and immunomodulatory functions [14, 15, 16], even after cryopreservation . Recently, many investigators have investigated a SHED bank for allogenic cell therapy, as well as autologous cell therapy [23, 29, 30]. Exfoliated deciduous teeth might therefore be a feasible cell source for MSC-based therapy for both pediatric and adult patients with liver dysfunction.
Although SHED are known to be capable of differentiating into hepatocyte-like cells in vitro , they have not been evaluated for their in vivo hepatogenic capacity or therapeutic efficacy in liver disorders. In this study, we reveal that SHED transplantation recovers the liver dysfunction of carbon tetrachloride (CCl4)-treated mice. The engrafted SHED convert directly into human hepatocyte-like cells without fusion in fibrous livers of CCl4-treated mice. Furthermore, these in vivo SHED-converted hepatocyte-like cells participate in the hepatic recovery via both direct (tissue replacement) and indirect (anti-fibrotic and anti-inflammatory effects) integration in CCl4-injured mouse livers.
Ethics statement and human subjects
Human samples were collected as discarded biological/clinical samples from healthy pediatric donors (5–7 years old) in the Department of Pediatric Dentistry of Kyushu University Hospital, Fukuoka, Japan. Procedures using human samples were conducted in accordance with Declaration of Helsinki, and were approved by Kyushu University Institutional Review Board for Human Genome/Gene Research (Protocol Number: 393-01). Written informed consent was obtained from each parent on behalf of the child donors. All animal experiments were approved by Institutional Animal Care and Use Committee of Kyushu University (Protocol Number: A21-044-1).
Isolation and culture of SHED
Isolation and culture of SHED were performed according to our previous reports [16, 23]. The detailed method is described in Additional file 1. To confirm whether our isolated cells were MSCs, the obtained passage 3 (P3) cells were assessed by a flow cytometric analysis as described previously . The P3 cells were also cultured under osteogenic, chondrogenic, and adipogenic conditions as described previously . The P3 cells were positive for CD146, CD73, CD105, and CD90, but negative for hematopoietic markers (CD34, CD45, CD14, and CD11b) (Figure S1A in Additional file 2). The P3 cells also exhibited multipotency into three types of classical mesenchymal lineage cells (Figure S1B–G in Additional file 2). These phenotypes indicated that our isolated SHED fulfilled minimal and standard criteria for MSCs . The P3 cells were therefore used for further experiments in this study.
Chronic liver fibrosis model in mice
Primary transplantation of SHED
One million SHED (P3) suspended in 100 μl phosphate-buffered saline (PBS) were intrasplenically transplanted into mice treated with CCl4 for 4 weeks (n = 5) (Fig. 1a). As a control, 100 μl PBS were infused intrasplenically into mice treated with CCl4 for 4 weeks (n = 5). The mice continuously received CCl4 twice a week for an additional 4-week treatment after the transplantation. All of the animals were sacrificed to harvest the livers and peripheral blood.
Colorimetric analysis and enzyme-linked immunosorbent assay of mouse serum and liver samples
Serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin were measured with a Multiskan GO microplate spectrophotometer (Thermo Scientific, Waltham, MA, USA) using commercially available kits according to the manufacturer’s protocol: ALP, LabAssay ALP Kit (Wako Pure Chemicals); ALT and AST, Transaminase CII-Test Kit (Wako Pure Chemicals); and total bilirubin, Bilirubin QuantiChrom Assay Kit (BioAssay Systems, Hayward, CA, USA). Liver hydroxyproline contents were measured with a Multiskan GO microplate spectrophotometer (Thermo Scientific) using a Hydroxyproline Assay Kit (Biovision, Milpitas, CA, USA). Serum mouse interleukin (IL)-6, IL-10, IL-17, transforming growth factor β1 (TGF-β1), and tumor necrosis factor alpha (TNFα) were also measured using Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA).
Histological and immunohistochemical analyses of mouse liver tissues
Tissue preparation, Masson’s trichrome staining, and immunohistochemical staining were performed as described in Additional file 1. The sections were observed under an Axio Imager M2 (Zeiss, Oberkochen, Germany) for morphometric assays, and five representative images from each mouse were selected randomly and were used to measure a percentage of fibrous tissue area or primary antibody-positive area using ImageJ software (NIH, Bethesda, MD, USA). Trichrome stained sections were analyzed to score the amount of liver disease using Ishak scoring .
Double immunofluorescent staining was performed as described in Additional file 1. The sections were observed under an Axio Imager M2 (Zeiss).
Quantitative real-time RT-PCR assay
Total RNAs were extracted and treated as described in Additional file 1. Real-time RT-PCR was subsequently performed using a TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA, USA) and target TaqMan probes (Applied Biosystems) (Table S1 in Additional file 3) with a Light Cycler 96 (Roche, Indianapolis, IN, USA). 18S ribosomal RNA was used for normalization.
Sorting of HLA-ABC-positive or HLA-negative cells from liver tissues of CCl4-treated mice transplanted with SHED
Livers of primary recipients (n = 5) were perfused with collagenase type H (0.1 mg/ml; Worthington Biochemicals, Lakewood, NJ, USA) in PBS and gently dispersed. Single suspended cells were stained with phycoerythrin (PE)-conjugated anti-human leukocyte antigen (HLA)-ABC (eBioscience, San Diego, CA, USA) and magnetic bead-conjugated anti-PE antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany). They were magnetically sorted using a MidiMACS separator (Miltenyi Biotec) equipped with a LD column (Miltenyi Biotec), and the positive and negative fractions were collected separately.
Cell fusion assay in HLA-positive cells
Magnetically sorted HLA-ABC-positive and HLA-negative fractions were stained with PE-conjugated anti-human major histocompatibility complex (MHC) class I HLA-ABC (eBioscience) and allophycocyanin (APC)-conjugated anti-mouse major MHC class I H-2Kb (eBioscience) antibody. The cells were measured with a FACS Verse flow cytometer (BD Biosciences, San Jose, CA, USA), and were analyzed by BD FACS Suite software (BD Biosciences).
Human-specific genome assay in HLA-positive cells
Genomic DNA was extracted from HLA-ABC-positive and HLA-negative fractions using a DNeasy Blood and Tissue Kit (Qiagen, Venlo, the Netherlands), and was amplified with a T-100 thermal cycler (Bio-Rad, Hercules, CA, USA) using Quick Taq HS DyeMix (TOYOBO, Osaka, Japan) and specific primer pairs by PCR assay. The specific primer pairs are presented in Table S2 in Additional file 3.
Characterization of HLA-positive cells as human hepatocytes
Sorted HLA-ABC-positive cells were cultured with Iscove’s modified Dulbecco’s medium (Invitrogen, Waltham, MA) supplemented with epidermal growth factor (EGF) (20 ng/ml; PeproTech, Rocky Hill, NJ, USA), fibroblast growth factor 2 (FGF2) (10 ng/ml; PeproTech), and hepatocyte growth factor (HGF) (20 ng/ml; PeproTech). Some cultures were stained with toluidine blue.
Expression of human hepatocyte-specific genes in HLA-positive cells was analyzed by RT-PCR with a T-100 thermal cycler (Bio-Rad) as described previously [16, 23]. The specific primer pairs are presented in Table S2 in Additional file 3. HepG2 cells (Riken, Tsukuba, Japan) were used as positive control. Human albumin and urea in the culture supernatants of HLA-positive cells were measured with a Multiskan GO microplate spectrophotometer (Thermo Scientific) using a Human Albumin ELISA Quantitation Set (AssayPro, St Charles, MO, USA) and a QuantiChrom Urea Assay Kit (Bioassay Systems), respectively.
Secondary transplantation of HLA-ABC-positive or HLA-negative cells sorted from liver tissues of CCl4-treated mice with primary transplantation of SHED
To understand whether SHED-derived in vivo-converted hepatocyte-like cells express hepatic function in vivo, we performed a secondary transplantation of the SHED-derived in vivo-converted hepatocyte-like cells into CCl4-damaged mice. The mice (n = 5 each) were treated with CCl4 for 4 weeks, and were then transplanted with 1 million HLA-positive or HLA-negative cells via the spleen and continuously received CCl4 twice a week for an additional 4-week treatment after the transplantation (shown in Fig. 6a). We also used CCl4-treated mice and nontreated mice without the cell transplant (n = 5 each). Finally, the peripheral blood serum and liver samples were harvested, and used for further experiments.
In vivo monitoring of transplanted cells
Cells were labeled with near-infrared (NIR) lipophilic carbocyanine membrane dye, 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR). The cells (1 × 107 in 10 ml PBS) were incubated with XenoLight DiR NIR Fluorescent Dye (10 μg/ml; Perkin Elmer, Waltham, MA, USA) for 30 minutes at 37 °C, and were then washed twice with PBS. In vivo optical imaging was performed to detect the transplanted cells. The labeled cells (1 ×106 in 100 μl PBS) were infused intrasplenically into CCl4-pretreated mice (n = 5). As a control for cell transplantation, nonlabeled SHED (1 × 106 in 100 μl PBS) were infused into CCl4-pretreated mice via the spleen (n = 5). Ventral images were captured from each animal group after 1 or 24 hours under an optical in vivo imaging system IVIS Lumina III (Perkin Elmer), and were analyzed using living image software (Perkin Elmer).
Statistical results are expressed as mean ± standard deviation (SD). Multiple group comparison was analyzed by one-way repeated-measures analysis of variance followed by the Tukey post hoc test using PRISM 6software (GraphPad, Software, La Jolla, CA, USA). P <0.05 was considered significant.
Transplanted donor SHED are capable of homing and differentiating into human hepatocyte-like cells in recipient livers of CCl4-injured mice
Mouse livers showed fibrosis after 4 weeks of treatment with CCl4 (data not shown). To address a therapeutic potential of SHED for liver disorders, SHED (1 × 106 per mouse) were intrasplenically injected into mice that had been treated with CCl4 for 4 weeks (Fig. 1a). We first investigated whether transplanted SHED were capable of engrafting in the CCl4-treated mouse liver parenchyma. DiR-labeled SHED were infused into a spleen of CCl4-treated mice. In vivo imaging demonstrated that the intensity of DiR was detected on the liver, as well as the spleen, 1 hour after transplantation (Fig. 1b). The signals were enhanced in both the liver and spleen 24 hours after transplantation (Fig. 1b). Non-CCl4-treated mice and non-SHED-infused CCl4-treated mice expressed no signal at 1 and 24 hours after transplantation (Fig. 1b). By the carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled cell trace technique, CFSE-labeled SHED were detected in CCl4-damaged mouse liver 1 day after the transplantation (Figure S2 in Additional file 2). Our immunohistochemical analysis also detected positive immunoreactions to anti-HLA-ABC antibody in spleens of CCl4-damaged mice, but negative immunoreaction to anti-HLA-ABC antibody in spleens of CCl4-damaged mice (Figure S3B, C in Additional file 2). In addition, no immunoreaction to anti-HLA-ABC and anti-hepatocyte paraffin 1 antibodies was detected in the kidneys and lungs of CCl4-damaged mice (Figure S3B, C in Additional file 2). These findings suggested that DiR-labeled SHED were recruited to CCl4-damaged liver from the transplanted site, the spleen.
SHED transplantation decreased CCl4-induced chronic fibrosis in mouse livers
To address whether SHED have therapeutic potential for liver disorders, SHED-transplanted CCl4-treated mice, as well as nontransplanted (PBS-injected) CCl4-treated mice, received continuous CCl4 injections for an additional 4 weeks (Fig. 1a). In week 8, the nontransplanted mice showed severe fibrous liver dysfunction (Fig. 2). A biochemical serum assay revealed that SHED transplantation markedly recovered the damaged liver functions (Fig. 2a). Masson trichrome staining showed that SHED transplantation reduced CCl4-enhanced fibrous deposition in the liver (Fig. 2b, c). The fibrous tissue area occupied 5.98 ± 1.35 %, 18.16 ± 3.36 %, and 8.89 ± 3.07 % of the recipient liver tissues in control mice, nontransplanted CCl4-treated mice, and SHED-transplanted CCl4-treated mice, respectively (Fig. 2c). The degree of hepatic fibrosis by Ishak score  was 0 ± 0, 3.60 ± 0.43, and 1.67 ± 0.41 of the recipient liver tissues in control mice, nontransplanted CCl4-treated mice, and SHED-transplanted CCl4-treated mice, respectively (Fig. 2d). Colorimetric and real-time PCR assays revealed that SHED transplantation significantly reduced the hydroxyproline content and collagen production in the CCl4-damaged liver tissues (Fig. 2e, f). Interestingly, HLA-ABC, hepatocyte paraffin 1, or human albumin-positive cells captured a similar area to the fibrous deposit region in the liver of nontransplanted CCl4-treated mice (Fig. 1d–f). To confirm the in vivo hepatogenic differentiation capacity and therapeutic efficacy of SHED in recipient CCl4-injured livers, we infused pediatric human gingival fibroblasts as a control for SHED transplantation in CCl4-treated mice (Figure S6A in Additional file 2). Immunohistochemical assay showed that no HLA-ABC, hepatocyte paraffin 1, or human albumin-positive human cells were detected in the recipient CCl4-damaged liver tissues (Figure S6B in Additional file 2). Biochemical assays demonstrated that human gingival fibroblast infusion did not recover the impaired hepatic function in CCl4-injected mice (Figure S6C in Additional file 2). Taken together, these findings indicated that SHED transplantation suppressed CCl4-enhanced fibrous deposition in the liver of CCl4-treated mice, and suggested that SHED directly/spontaneously transdifferentiated into human hepatocytes in CCl4-damaged livers.
Donor SHED are capable of differentiating into human hepatocyte-like cells without fusion in CCl4-injured mouse livers
Further RT-PCR assay demonstrated that the purified HLA-ABC-positive cells expressed human hepatocyte-specific genes, albumin, cytochrome P450 1A1, cytochrome P450 3A7, fumarylacetoacetase, tyrosine aminotransferase, uridine 5′-diphospho (UDP)-glucuronosyltransferase, transferrin, and transthyretin (Fig. 5f). However, the expression levels of human hepatocyte-specific genes in the purified HLA-ABC-positive cells were lower when compared with human hepatocyte cell line HepG2 (Fig. 5f). By ELISA and colorimetric assay, human albumin, urea, and blood urea nitrogen were detected at 4.8 ± 0.085 ng/ml, 0.47 ± 0.01 mg/dl, and 0.22 ± 0.005 mg/dl, respectively, in the culture supernatant of HLA-positive cells cultured with EGF, FGF2, and HGF stimulation for 3 days. Taken together, these findings indicate that SHED might show a potential for transdifferentiating into functional human hepatocytes, at least partially, without fusing with host mouse hepatocytes in fibrotic livers of CCl4-treated mice.
Secondary transplantation of SHED-derived human hepatocyte-like cells purified from primary CCl4-injured recipient livers recovered hepatic dysfunction of CCl4-treated mice
An immunohistochemical examination demonstrated that HLA-ABC-positive, hepatocyte paraffin 1-positive, and human albumin-positive cells were observed in the interlobular and portal regions corresponding to the fibular deposited area in liver tissues of CCl4-treated mice that underwent secondary transplant with HLA-ABC-positive cells 4 weeks after the primary transplant (Fig. 6c). The HLA-ABC-positive, hepatocyte paraffin 1-positive, and human albumin-positive cell areas were 23.22 ± 6.81 %, 19.31 ± 5.06 %, and 17.80 ± 4.71 % in the secondary recipient livers (Fig. 6d). The immunohistochemically positive areas expressed a similar rate to the liver fibrous area of nontransplanted CCl4-injured mice (Figure S8 in Additional file 2). No immunoreactivity against HLA-ABC, hepatocyte paraffin 1, or human albumin was detected in the liver tissues of CCl4-induced mice that underwent secondary transplant with HLA-ABC-negative cells (Fig. 6c) or in nontransplanted CCl4-induced mice and non-CCl4-induced mice (data not shown). ELISA also showed that serum human albumin was detected in CCl4-treated mice that underwent secondary transplant with HLA-ABC-positive cells, but not in CCl4-treated mice that underwent secondary transplant with HLA-ABC-negative cells, nontransplanted CCl4-treated mice, and non-CCl4-treated mice (Fig. 6e).
Severe shortage of donor organs is a major challenge for liver transplantation . Because of their unique capacities for homing and hepatic differentiation, MSCs and hematopoietic stem cells have been receiving attention as a source for cell therapy as an alternative to liver transplantation . Transplantation of isolated mature hepatocytes has been used as an experimental therapy for liver disease in a limited number of cases. Recently, 100 cases of hepatocyte transplantation have been reported. Clinically, hepatocyte transplants express a proven efficiency, particularly in cases of metabolic liver disease where reversal or amelioration of the characteristic symptoms of the disease is easily quantified. However, no patients are completely corrected of a metabolic liver disease for a significant amount of time by hepatocyte transplantation alone . MSC transplantation [12, 13, 14], as well as hematopoietic stem cell transplantation [41, 42], can successfully treat liver failure in animal models. MSCs exhibit a greater therapeutic efficacy with regard to homing and reducing fibrosis in comparison with hematopoietic stem cells in injured livers [43, 44]. In the present study, we demonstrated that SHED transplantation improved CCl4-induced liver fibrosis and hepatic dysfunction via inertness of activated hepatic stellate cells and by replacement of damaged tissue with transplanted SHED-derived hepatocyte-like cells. These findings therefore suggest that SHED might be a promising MSC source for liver regeneration.
The present study demonstrated that SHED transplantation markedly suppressed not only the pathological activation of hepatic stellate cells, but also the excessive infiltration of Kupffer cells and T cells in CCl4-damaged mouse livers. Furthermore, SHED transplantation significantly reduced the enhanced production of fibrogenic and inflammatory factors, such as TGF-β1, TNFα, MMP2, MMP9, TIMP1, TIMP2, IL-6, and IL-17, and enhanced the expression of the anti-inflammatory factor IL-10 in CCl4-induced fibrous livers. Activated hepatic stellate cells contribute to liver fibrosis via abnormal production of MMP2, TIMP1, and TIMP2 through the secretion of various inflammatory cytokines from Kupffer cells and T cells [34, 35]. SHED can induce Tregs and suppress Th17 cells and monocytes/dendritic cells [16, 17]. Transplanted SHED might therefore suppress immune responses and promote anti-fibrotic regulation by affecting hepatic stellate cells, Kupffer cells, and T cells in CCl4-damaged mouse livers.
We speculate that a considerable number of transplanted SHED might be rejected immunologically owing to the present xenogeneic transplantation system and nonimmunosuppressive status in immunocompetent mice. We also consider a possibility that donor SHED and the differentiated hepatocytes, as well as recipient hepatocytes, might be damaged by chronic CCl4 stimuli. On the contrary, a result that donor SHED survived to differentiate into human hepatocytes in CCl4-injured liver tissues suggests that the donor cells maintained higher toxic resistance compared with recipient cells, and supports that donor SHED, at least partially, showed a tolerance to host immune response, even under nonimmunosuppressive condition, in immunocompetent mice. Furthermore, SHED transplantation did not induce any heavy infiltration of lymphocyte-like cells, as well as any change of structural components, in other tissues including the kidney, lung, and spleen of CCl4-treated mice. On the other hand, SHED transplantation suppressed the immune reaction in CCl4-treated mice. These findings support that donor SHED did not cause any graft versus host disease-like reaction. Taken together, these findings suppose that SHED might exhibit safe immunology in the present xenogeneic transplantation system. Less HLA-DR expression and active immunomodulatory function of SHED may support a low immunogenicity and can acquire immune tolerance in vivo [16, 45]. Further study will be necessary to confirm the immunological safety of SHED as a donor for allogenic transplantation, as well as autologous transplantation, for liver patients.
The liver is a site of hematopoiesis in the fetus, so bone marrow hematopoietic stem cells have been considered an origin for hepatocytes in adults [46, 47]. Transplanted hematopoietic stem cells fuse with host hepatic cells to repopulate the liver as functional hepatocytes [36, 37]. On the other hand, a nonfusion origin of human hepatocytes was proposed in mouse liver transplanted with human hematopoietic cells [48, 49, 50]. Engrafted bone marrow MSCs directly transdifferentiated into hepatocytes without cell fusion in rat livers . Therefore, whether donor human cells fuse with recipient hepatic cells in mouse liver has not yet been fully understood. The presented three different approaches with a cell sorting technique of MHC class I antigen HLA-ABC-expressed human cells from the recipient mouse liver were carried out to evaluate the possibility of fusion between donor human MSCs and recipient murine hepatocytes. By flow cytometric analysis using human and mouse specific antibodies against MHC class I antigen, cell fusion of the donor cells and recipient cells was excluded. PCR analysis using human and mouse specific primers also omits the possibility of cell fusion. In a further secondary transplant assay, HLA-ABC-negative cells have in vivo differentiation capacity into human hepatocytes. These results indicate that donor-derived human hepatocytes have only human genetic and immunological properties, suggesting that cell fusion of donor SHED and recipient hepatocytes in the hepatogenic process may be a rare or nonexistent phenomenon in recipient CCl4-injured mice. From another point of view, cell fusion between recipient hepatocytes and hematopoietic stem cells might lead to genetic instability and formation of cancer stem cells . Human MSCs exhibit a low tumorigenic potential in vivo  and in vitro . The present findings indicate that SHED may provide an attractive and safe source for stem cell-based liver regeneration. However, a long-term in vivo experiment will be necessary to assess the safety and tumorigenic risk(s) after SHED transplantation in damaged livers.
The present immunohistochemical findings suggest that intrasplenically infused donor SHED are transported into recipient liver through the portal vein system via the splenic vein, and penetrated into CCl4-damaged fibrous area via the interlobular portal veins. However, the mechanism underlying in vivo homing and hepatic potential of transplanted MSCs, including SHED, remains unclear. In vivo homing and hepatic potential of MSCs might be regulated by a microenvironment of injured liver tissues. Liver contributes to a niche for hematopoietic stem cells in the fetus  and in patients with osteomyelofibrosis . Hepatic stellate cells support hematopoiesis in fetal livers , and activated hepatic stellate cells release a factor associated with stem cell homing and migration, C-X-C motif chemokine 12 , and a factor promoting hepatocyte proliferation and differentiation, HGF . In addition, hepatic stellate cells modulate a hepatogenic potential of bone marrow MSCs . These previous studies suggest that activated hepatic stellate cells might function as a niche to modulate the homing and hepatic differentiation of transplanted MSCs. Further studies will be necessary to elucidate cellular and molecular mechanism(s) responsible for in vivo homing and hepatic potential of transplanted MSCs, including SHED.
In this study, purified HLA-ABC-positive cells from liver tissue of SHED-transplanted CCl4-treated mice confirmed the expression of several characteristics as human hepatocyte-like cells. The present secondary transplantation into CCl4-treated mice analysis demonstrates that purified HLA-ABC-positive cells express a homing capacity and a treatment efficacy in CCl4-injured mice, suggesting that in vivo-converted SHED-derived hepatocytes may function as human hepatocytes. Chimeric human livers with more than 90 % human hepatocytes are successfully developed in murine models [60, 61]. A recently reported novel tissue engineering approach generated a transplantable recellularized liver graft with human hepatocytes and MSCs using xenogeneic decellularized livers [62, 63]. The present in vivo serial transplantation assay demonstrated that SHED-derived direct-converted hepatocytes exhibit chimerism and therapeutic effect in CCl4-damaged mouse livers. These results suggest that in vivo-generated human hepatocyte-like cells derived from donor SHED may provide an alternative source for banking of human hepatocytes and development of human chimeric livers in vivo and ex vivo.
In summary, this report provides a foundation for SHED-based liver regenerative medicine. Further studies will be required to elucidate whether this practical and unique approach can be applied clinically for patients with liver disorders, such as liver fibrosis, metabolic diseases, or some coagulopathies.
The authors are very thankful to Mr Brian Quinn for his English assistance with writing. They also appreciate Ms Tomoko Yamazaki (Department of Pediatric Surgery, Kyushu University Graduate School of Medical Sciences) for her excellent assistance and Dr Soichiro Sonoda (Department of Molecular Cell Biology and Oral Anatomy, Kyushu University Graduate School of Dental Science) for his histological assistance and writing support during this study. This work was supported by grants from the Japan Society for the Promotion of Science, including Grant-in-Aid for Scientific Research (A) (grant number 25253094 to TT), Grant-in-Aid for Scientific Research (B) (grant number 25293405 to TY), and Grant-in-Aid for Challenging Exploratory Research Project (grant numbers 23659618 and 25670744 to TT and grant number 24659815 to TY), from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Translational Research Grant of Center for Clinical and Translational Research Seeds B3 to TT, and from the Ministry of Health, Labor and Welfare for Research on Rare and Intractable Diseases (grant number H26-040) to TT. This research is also partially supported by the Translational Research Network Program from Japan Agency for Medical Research and Development, AMED. The authors appreciate Professor Fusanori Nishimura (Department of Periodontology, Kyushu University Graduate School of Dental Science) for his technical assistance through the program for the Promotion of Strategic International Research Network accelerating Brain Rotation (S2605) by the Japan Society for the Promotion of Science.
- 5.Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;22:83–92.Google Scholar
- 27.Bishi DK, Mathapati S, Venugopal JR, Guhathakurta S, Cherian KM, Ramakrishna S, et al. Trans-differentiation of human mesenchymal stem cells generates functional hepatospheres on poly(L-lactic acid)-co-poly(ε-caprolactone)/collagen nanofibrous scaffolds. J Mater Chem B. 2013;1:3972–84.CrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.